Skip to main content
Breast Cancer Research : BCR logoLink to Breast Cancer Research : BCR
. 2020 May 20;22:52. doi: 10.1186/s13058-020-01294-7

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Lori J Goldstein 1, Raymond P Perez 2,3, Denise Yardley 4,10, Linda K Han 5,6, James M Reuben 7, Hui Gao 7, Susan McCanna 8, Beth Butler 8, Pier Adelchi Ruffini 8, Yi Liu 9, Roberto R Rosato 9, Jenny C Chang 9,
PMCID: PMC7238734  PMID: 32434589

Correction to: Breast Cancer Res (2020) 22:4

https://doi.org/10.1186/s13058-019-1243-8

After publication of the original article [1], the authors identified two errors in the Author details:

  1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley’s affiliation in addition to Tennessee Oncology.

  2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.

Reference

  • 1.Goldstein LJ, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Res. 2020;22:4. doi: 10.1186/s13058-019-1243-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Breast Cancer Research : BCR are provided here courtesy of BMC

RESOURCES